C REACTIVE PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASES

As a marker of systemic inflammation, raised (C-reactive protein (CRP)) concentrations which are still within the normal range have been associated with an increased inflammation of chronic renal diseases (CRD). The current study aimed to establish potential determinats of raised CRP concentrations in patients who treated in Heamodialysis room,then study the relationship between CRP& some biochemical parameters related CRD We used a CRP latex reagents Kit which is based on an immunological reaction between CRP antisera bounded to the biologically inert latex particles or with CRP in the test specimens of 19 patients with (CRD) mean age 48 years ,range = 30?65 & in 21 healthy subjects as control group their age range = 30 ?45 years. The results are classified according to visible agglutination to: 1-A positive result / is indicated by the obvious agglutination pattern of the latex, in a clear solution. 2-A negative result / is indicated by no change in the latex suspension on the test slide. Then, we correlated the results of the precipitin test with the quantitative data on C-reactive protein. This study has found that: CRP concentrations in patients with CRD were increased very clearly than normal subjects , and established that CRP concentration in male was more than in female for patients specimens. Biochemical studies have shown raising (CRP) concentration is a marker of systemic inflammation. The relation between CRP & S.creatinine ,hemoglobine ,blood sugar is negative ,while positive with blood urea . Other biochemical parameter related to CRD'' blood urea, blood creatinine & hemoglobine and blood sugar'' were assayed for both subjects in order to asses the disease by compared the results. Abbreviation: CRP:C-reactive protein, CRD: Chronic renal diseases, F: Female, M: Male, Hb: hemoglobin, BU: blood Urea, S.Cr: Serum creatinine, BS: blood sugar, nCRP: native CRP, MCRP: Matified CRP.

Download Full-text

The effect of hepcidin on components of metabolic syndrome in chronic kidney disease: a cross-sectional study

Revista da Associação Médica Brasileira ◽

10.1590/1806-9282.66.8.1100 ◽

2020 ◽

Vol 66 (8) ◽

pp. 1100-1107

Author(s):

Sibel Gökçay Bek ◽

Berna Üstüner ◽

Necmi Eren ◽

Zeynep Sentürk ◽

Betül Kalender Gönüllü

Keyword(s):

Metabolic Syndrome ◽

Chronic Kidney Disease ◽

Uric Acid ◽

Kidney Disease ◽

Cross Sectional Study ◽

Renal Diseases ◽

Sectional Study ◽

C Reactive Protein ◽

Cross Sectional ◽

Reactive Protein

SUMMARY BACKGROUND Hepcidin is an important regulator of iron homeostasis. OBJECTIVES This cross-sectional study was conducted to evaluate the association between hepcidin and components of metabolic syndrome in patients with chronic kidney disease (CKD). DESIGN AND SETTING 103 CKD patients and 59 healthy volunteers were included in the study from the University Hospital. METHODS Serum hepcidin levels were measured by enyzme-linked immunosorbent assay (ELISA) test. As for the study parameters, age, sex, body mass index, renal diseases, serum biochemistry, complete blood count, iron and total iron-binding capacity, ferritin, high-sensitive C-reactive protein (hsCRP), C- reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. RESULTS The mean age of the patients was 58.63 ± 11.8 years. Hepcidin level was significantly associated with hypertension and higher uric acid levels (P < 0.05). There was a positive correlation between hepcidin and urea, uric acid, creatinine, ferritin, CRP, ESR, phosphorus, triglyceride, low-density lipoprotein (LDL), proteinuria and albuminuria in 24-hour urine collection. A negative correlation was found between hepcidin and estimated glomerular filtration rate (eGFR), hemoglobin, hematocrit, calcium, 25 OH vitamin D, pH, and bicarbonate levels. CONCLUSION Hepcidin, a well-known hormone regulator of iron metabolism, may play an important role in the pathogenesis of metabolic syndrome in patients with CKD, and further studies might delineate in-depth its potential as a promising early marker in these patients.

Download Full-text

C - REACTIVE PROTEIN AND ITS ASSOCIATION WITH SERUM URIC ACID AND BICARBONATE LEVEL IN COPD

10.36106/gjra/0406215 ◽

2021 ◽

pp. 20-21

Author(s):

Omprakash Shyoran ◽

Mahadev Choudhary ◽

Jai Prakash Yogi ◽

Bushra Fiza ◽

Maheep Sinha ◽

...

Keyword(s):

Uric Acid ◽

Serum Uric Acid ◽

Respiratory Acidosis ◽

Renal Diseases ◽

Bicarbonate Level ◽

C Reactive Protein ◽

Reactive Protein ◽

Copd Patients ◽

Lactating Females ◽

The Individual

AIM: The study was planned to evaluate the association of C - reactive protein with Serum Uric Acid and Bicarbonate Level in COPD. MATERIAL AND METHODS: In the present study total 100 (n=100) patients diagnosed for COPD, were enrolled for the study. Patients with neoplastic pathologies, pneumonia and Liver or renal diseases, pregnant and lactating females were excluded from the study. RESULT: The mean level of Serum Bicarbonate, C-reactive protein and uric acid were signicantly higher in COPD patients. A signicant association was observed (p ≤ 0.0001). CONCLUSION: In the present study higher bicarbonate levels that could be the individual biomarker which can assess the respiratory acidosis and CRP and Uric Acid levels judges the severity the disease.

Download Full-text

The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome

Thrombosis and Haemostasis ◽

10.1160/th13-06-0499 ◽

2013 ◽

Vol 110 (11) ◽

pp. 940-958 ◽

Cited By ~ 14

Author(s):

Federico Carbone ◽

François Mach ◽

Roberto Pontremoli ◽

Francesca Viazzi ◽

Fabrizio Montecucco

Keyword(s):

Metabolic Syndrome ◽

Basic Research ◽

Renal Diseases ◽

C Reactive Protein ◽

Alcoholic Fatty Liver ◽

Reactive Protein ◽

Multiplicative Effect ◽

Liver And Kidney ◽

And Function ◽

Alcoholic Fatty Liver Disease

SummaryThe increased atherothrombotic risk in patients with metabolic syndrome (MetS) has been classically explained by the multiplicative effect of systemic concomitant pro-atherosclerotic factors. In particular, centripetal obesity, dyslipidaemia, glucose intolerance, hypertension (differently combined in the diagnosis of the disease) would be expected to act as classical cardiovascular risk conditions underlying accelerated atherogenesis. In order to better understand specific atherosclerotic pathophysiology in MetS, emerging evidence focused on the alterations in different organs that could serve as both pathophysiological targets and active players in the disease. Abnormalities in adipose tissue, heart and arteries have been widely investigated in a variety of basic research and clinical studies in MetS. In this narrative review, we focus on pathophysiological activities of the liver and kidney. Considering its key role in metabolism and production of soluble inflammatory mediators (such as C-reactive protein [CRP]), the liver in MetS has been shown to be altered both in its structure and function. In particular, a relevant amount of the fat accumulated within this organ has been shown to be associated with different degrees of inflammation and potential insulin resistance. In humans, non-alcoholic fatty liver disease (NAFLD) has been described as the hepatic manifestation of MetS. In an analogous manner, epidemiological evidence strongly suggested a “guilty“ association between MetS and chronic kidney disease (CKD). Some biomarkers of hepatic (such as C-reactive protein, TNF-alpha or other cytokines) and renal diseases (such as uric acid) associated with MetS might be particularly useful to better manage and prevent the atherothrombotic risk.

Download Full-text